{"id":"hip0612","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperphosphatemia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Stomatitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HIP0612 targets FGFR, a receptor tyrosine kinase frequently dysregulated in various cancers through gene amplification, mutation, or translocation. By inhibiting FGFR signaling, the drug suppresses downstream proliferation and survival pathways in FGFR-dependent tumors. This mechanism is particularly relevant in cancers with FGFR alterations, including certain gastric, bladder, and other solid tumors.","oneSentence":"HIP0612 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:42:01.778Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"FGFR-altered gastric cancer"},{"name":"FGFR-altered urothelial cancer"}]},"trialDetails":[{"nctId":"NCT05656092","phase":"PHASE3","title":"A Study to Evaluate the Effiacy and Safety of HIP0612 in Patients With Gastric Ulcer","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2023-03-06","conditions":"Gastric Ulcer","enrollment":199}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HIP0612","genericName":"HIP0612","companyName":"Hanmi Pharmaceutical Company Limited","companyId":"hanmi-pharmaceutical-company-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HIP0612 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells. Used for FGFR-altered gastric cancer, FGFR-altered urothelial cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}